GlobeNewsWire
10 Nov 2026, 06:00 UTC · 1d ago
Impact · against what's priced in
Valneva's five-year antibody persistence data for IXCHIQ provides positive confirmation of long-term vaccine durability. However, because the results are consistent with previous data and align with company expectations, the immediate impact on valuation is limited.
No priced-in read yet
What the story claims
2 claims · scored −1 bearish … +1 bullish · 1 new · 1 priced in
Valneva reported a 94% seroresponse rate five years after a single dose of the IXCHIQ® chikungunya vaccine.
Newreported today, November 10, 2026
More positive than 76% of claims this week
The five-year antibody persistence results were consistent with previously reported persistence data.
Priced in
Continue reading
5 related stories
The report of a 94% seroresponse rate five years after a single dose validates the vaccine's durable profile, though the fact that results were consistent with prior data limits the catalyst potential.
Read from the article alone
Scored by the NIS engine · methodology.
So whatMinimal deviation from historical trends suggests no immediate revision to current valuation multiples.
More positive than 42% of claims this week
Which stocks this story touches
More positive than 89% of ticker scores this week
The company reported positive five-year antibody persistence data for its chikungunya vaccine IXCHIQ.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
PRNewsWire
10h ago
+1.6%
Price agrees with the score
$5.75 vs $5.66 close before publication (Nov 9) · not market-adjusted
VALN chart →
